



\$1.45M Grant to Hudson Institute for Collaboration with Noxopharm

Highlights

- **\$1.45M granted to Noxopharm collaborator Hudson Institute of Medical Research for research into novel therapeutics to block inflammation**
- **Noxopharm's subsidiary, Pharmorage, named on the grant as the collaborator to commercialise any promising drug candidates generated**
- **Non-dilutive funding to be applied to Noxopharm's preclinical collaborative research program with Hudson Institute of Medical Research**
- **Has the potential to extend the Company's IP portfolio of anti-inflammatory therapeutics**

Sydney 22nd June 2022: Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce that the Victorian Government has granted A\$1.45M to Noxopharm collaborator, **Hudson Institute of Medical Research**, to fund the joint development program of novel anti-inflammatory compounds. Noxopharm's wholly-owned subsidiary, Victoria-registered Pharmorage Pty Ltd, is named on the grant as the collaborator that will design and synthesise the compounds with the view of commercialising any promising drug candidates generated by the research.

The research aims to identify novel drug compounds that dampen harmful excessive inflammation associated with COVID-19 infection. Should any identified drug candidates show promise of broader inflammatory indications it is anticipated that Noxopharm will investigate their commercial and scientific potential.

Reducing excessive inflammation during COVID-19 infection is a critical part of limiting virus-associated hospitalisations, intensive care admissions, and deaths. In addition, mounting evidence suggests that chronic inflammation underpins post-infectious syndromes associated with long-COVID, which may impact as many as 60% of COVID-19 patients.¹ Therefore, this research aims to fast-track the therapeutic development of new, targeted therapies to help manage both acute and chronic inflammation.

Noxopharm CEO Dr Gisela Mautner, said: "Noxopharm has built a network of collaborators spanning world-renowned academic and government institutions, including Hudson Institute. We are excited the collaboration with Hudson Institute is attracting this level of non-dilutive funding. We look forward to progressing our work in inflammatory diseases with them."

The research is set to commence shortly and will continue for approximately two years. Noxopharm will continue to keep the market informed as this work progresses.

¹ Blomberg, B., Mohn, K.G.I., Brokstad, K.A. *et al.* Long COVID in a prospective cohort of home-isolated patients. *Nat Med* **27**, 1607–1613 (2021). <https://doi.org/10.1038/s41591-021-01433-3>

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its lead clinical-stage drug candidate Veyonda[®], plus two innovative technology platforms – Chroma[™] (oncology) and Sofra[™] (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

About Hudson Institute of Medical Research

A global bioscience medical research leader, Hudson Institute's sole focus is on powering breakthrough scientific discoveries into improved health care that will transform lives. We strive to improve human health through ground-breaking, collaborative, medical research discoveries and the translation of these to real world impact.

Hudson Institute scientists research five areas of medical need

- Inflammation
- Reproductive health and pregnancy
- Infant and child health
- Cancer
- Hormones and health

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@atomicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and



events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.